The hypnotic activity of diazepam was compared with that of inactive placebo in a double- blind, randomized study in 40 surgical patients the night before their scheduled procedures. Diazepam per os (10mg) produces a pattern of response that differed markedly from that of the placebo. The patient receiving diazepam fell asleep sooner, slept more soundly and steadily and more felt they had been helped to sleep, while fewer awoke during the night. The significant difference Was obtained in both hypnotic and ataractic effects between diazepam and inactive placebo. Neither diaxepam nor inactive placbo caused marked changes in vital signs or any serious side effects.
Diazepam* ; Humans ; Vital Signs

Pheochromocytoma is the cause of hypertension in 0.1% of the hypertencive patits, and in 10% of these cases, the tumor is bilateral. Therefore bilateral pheochromocytoma is very rare. The following is a report of the anesthetic methods employed in the surgical management of a case of bilateral pheochromocytoma which was performed in stages at PNUH, between June 4th and June 12, 1986. The staged operation reduced the instability of the vital signs caused by concurrent manipulation of the bilateral pheochromoytoma and facilitated tumor removal.
Hypertension ; Pheochromocytoma* ; Vital Signs

Pheochromocytoma is the cause of hypertension in 0.1% of the hypertencive patits, and in 10% of these cases, the tumor is bilateral. Therefore bilateral pheochromocytoma is very rare. The following is a report of the anesthetic methods employed in the surgical management of a case of bilateral pheochromocytoma which was performed in stages at PNUH, between June 4th and June 12, 1986. The staged operation reduced the instability of the vital signs caused by concurrent manipulation of the bilateral pheochromoytoma and facilitated tumor removal.
Hypertension ; Pheochromocytoma* ; Vital Signs

OBJECTIVES: The objective of this study was to evaluate the efficacy of Unicenta (UNCNT) and Melsmon in women with the menopausal symptoms, by analysing the changes in the Kupperman index (primary endpoint), and the hormonal change (secondary endpoint). METHODS: This is a randomized, multi-Center, double-Blind, parallel, non-inferiority clinical study of four different tertiary medical centers. We began the participant recruitment in September 2011, with 218 patients applied over 7 months. All participants had the last visit in April 2012. RESULTS: The Unicenta injection was not inferior to that of Melsmon as measured by the Kupperman index following the injection in both the intent-to-treat and the per-protocol populations (P = 0.63, P = 0.85, respectively). Side effects occurred in 14.0% of the cases (15 patients/18 cases) in the case group, and in 12.6% (14 patients/15 cases) in the control group (P value=0.7599). None were reported to be associated with the medication. The laboratory results and the vital signs showed no statistically significant risk for safety. CONCLUSION: The study showed that Unicenta is not inferior to Melsmon in the change of the Kupperman index after 12 days of injection. The efficacy and safety of Unicenta was shown, with the improvement of the menopausal symptoms.
Female ; Humans ; Menopause ; Vital Signs

BACKGROUND/AIMS: For proper sedation during endoscopic submucosal dissection (ESD), propofol has been widely used. This study aimed to compare the levels of sedation and tolerance of patients treated with midazolam (M group) and a combination of midazolam and propofol (MP group) during ESD. METHODS: A total of 44 consecutive patients undergoing ESD were randomly assigned to the two groups. In the M group, 2 mg of midazolam was given repeatedly to maintain after a loading dose of 5 mg. The MP group initially received 5 mg of midazolam and 20 mg of propofol. Then, we increased the dosage of propofol by 20 mg gradually. RESULTS: The average amount of midazolam was 12 mg in the M group. In the M group, 10 patients were given propofol additionally, since they failed to achieve proper sedation. The average amount of propofol was 181 mg in the MP group. Procedure time, vital signs and rates of complications were not significantly different between two groups. Movement of patients and discomfort were lower in the MP group. CONCLUSIONS: During ESD, treatment with propofol and a low dose of midazolam for sedation provides greater satisfaction for endoscopists compared to midazolam alone.
Humans ; Midazolam ; Propofol ; Vital Signs

BACKGROUND/AIMS: For proper sedation during endoscopic submucosal dissection (ESD), propofol has been widely used. This study aimed to compare the levels of sedation and tolerance of patients treated with midazolam (M group) and a combination of midazolam and propofol (MP group) during ESD. METHODS: A total of 44 consecutive patients undergoing ESD were randomly assigned to the two groups. In the M group, 2 mg of midazolam was given repeatedly to maintain after a loading dose of 5 mg. The MP group initially received 5 mg of midazolam and 20 mg of propofol. Then, we increased the dosage of propofol by 20 mg gradually. RESULTS: The average amount of midazolam was 12 mg in the M group. In the M group, 10 patients were given propofol additionally, since they failed to achieve proper sedation. The average amount of propofol was 181 mg in the MP group. Procedure time, vital signs and rates of complications were not significantly different between two groups. Movement of patients and discomfort were lower in the MP group. CONCLUSIONS: During ESD, treatment with propofol and a low dose of midazolam for sedation provides greater satisfaction for endoscopists compared to midazolam alone.
Humans ; Midazolam ; Propofol ; Vital Signs

We report a case of left adrenal pheochromocytoma in 17-year-old girl, we observed all of vital sign were returned to normal in 19-th postoperative day
Adolescent ; Female ; Humans ; Pheochromocytoma* ; Vital Signs

Hemodynamic monitoring continuously checks hemodynamic variables for problems so that the clinician can treat them when a patient's vital signs are unstable. There are many different monitoring systems, and many new technologies were developed over the past three decades. It is challenging to understand the many monitoring system in the intensive care units, for example. However, all such monitoring systems are based on the general principle of monitoring oxygen transport to a peripheral organ. In this review, from conventional to recent principles, general concepts and paradigm shifts of hemodynamic monitoring will be discussed.
Hemodynamics* ; Intensive Care Units ; Oxygen ; Vital Signs

Intracranial pressure was monitored in 23 patients, either who exhibited an increase in pressure or who were considered at risk for the developement of intracranial hypertention. The intracranial pressure was measured while the patient was in the position from supine to 50 degree of head elevation. The intracranial pressure was decreased during head elevation, but 8 cases(34.8%) were not changed. The maximal cerebral perfusion pressure was seen at 50 degree of head elevation(52.2%), next 30 degree(21.7%) and 40 degree(7.4%) in orders. The changes of vital sign were not significant during head elevation. To control the intracranial pressure, the patient who were managed in the position of 30degrees and 50degrees head elevation showed most effective cerebral perfusion pressure without any significant changes of the vital sign and central venous pressure.
Central Venous Pressure ; Head* ; Humans ; Intracranial Pressure* ; Perfusion* ; Vital Signs*

OBJECTIVE: The purpose of this study is to design a portable ECG monitoring system, which integrates up-to-date PDA and RF communication technology, and to acquire the subject's biomedical signal without any constraint. METHODS: The developed system is composed of a transmitter and a receiver. The transmitter has a MCU (microcontroller), three-axial acceleration sensor, ECG amplifier and Zigbee communication controller. It has two types of transmission mode, which are total signal transmission mode and HR (heart rate)/SC (step count) transmission mode. The receiver has a MCU, Serial Communication IC, and Zigbee communication controller. It forwards the received data to PDA, where the data can be stored and displayed. RESULTS: In total signal transmission mode, it can send data 60 packets per second whose transmission speed corresponds to 300 ECG samples and 60 acceleration samples. In HR/SC transmission mode, it can calculate heart rate from ECG data with 216 samples per second and step count from acceleration data and send a packet every cardiac cycle. CONCLUSION: Using this device, a new method of remote monitoring both vital sign and activity is realized. A PDA-based wireless ECG system enables patients to be monitored during their daily living, without any constraints. Also, this method will reduce medical costs in the aged society.
Acceleration ; Communication ; Electrocardiography* ; Heart Rate ; Humans ; Vital Signs